Tundidor, IsabelSeijo Vila, MartaBlasco Benito, SandraRubert Hernández, MaríaAdámez, SandraAndradas, ClaraManzano, SaraÁlvarez López, IsabelSarasqueta, CristinaVilla Morales, MaríaGonzález Lois, CarmenRamírez Medina, EstherAlmoguera, BelénSánchez López, Antonio J.Bindila, LauraHamann, SigridArnold, NorbertRöcken, ChristophHeras Murillo, IgnacioSancho, DavidMoreno Bueno, GemaCaffarel, María M.Guzmán Pastor, ManuelSánchez García, María CristinaPérez Gómez, Eduardo2024-04-092024-04-092023-05-302041-172310.1038/s41467-023-38750-9https://hdl.handle.net/20.500.14352/102906Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents 70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://www.nature.com/articles/s41467-023-38750-9open access577.1618.19-006Bioquímica (Biología)Oncología2403 Bioquímica3201.01 Oncología